



Rhofade™ (oxymetazoline) – New Drug Approval

- On January 19, 2017, [Allergan announced](#) the FDA approval of [Rhofade \(oxymetazoline\)](#) 1% cream, for the topical treatment of persistent facial erythema associated with rosacea in adults.
- Rosacea affects an estimated 16 million Americans. Persistent facial redness is cited as the most common sign of rosacea, and may resemble a flushing or sunburn that does not go away.
- The approval of Rhofade was based on two vehicle-controlled trials in 885 adult patients with moderate or severe rosacea. The primary efficacy endpoint was the proportion of patients with at least a 2-grade reduction in erythema from baseline on day 29 at hours 3, 6, 9, and 12.
 - In both clinical trials, more patients in the Rhofade arm achieved the primary endpoint compared to the vehicle arm.
- Warnings and precautions of Rhofade include potential impacts on cardiovascular disease, potentiation of vascular insufficiency, and risk of angle closure glaucoma.
- The most common adverse events ($\geq 1\%$) with Rhofade use were application site dermatitis, worsening inflammatory lesions of rosacea, application site pruritus, application site erythema, and application site pain.
- The recommended topical dose of Rhofade is a pea-sized amount applied once daily, in a thin layer to cover the entire face (forehead, nose, each cheek and chin), avoiding the eyes and lips.
 - Rhofade is not for oral, ophthalmic, or intravaginal use.
- Allergan plans to launch Rhofade in May 2017. Rhofade will be available as a 1% topical cream.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.